3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
205
Breast Neoplasms
187
Neoplasms
167
Leukemia, Myeloid, Acute
164
Multiple Myeloma
157
Lymphoma
120
Melanoma
117
Neoplasm Metastasis
114
Lymphoma, Non-Hodgkin
110
Prostatic Neoplasms
109
Leukemia
107
Colorectal Neoplasms
96
Recurrence
91
Leukemia, Lymphocytic, Chronic, B-Cell
90
Pancreatic Neoplasms
85
Ovarian Neoplasms
85
Myelodysplastic Syndromes
83
Lung Neoplasms
83
Lymphoma, Follicular
78
Glioblastoma
78
Precursor Cell Lymphoblastic Leukemia-Lymphoma
77
Lymphoma, Large B-Cell, Diffuse
77
Hodgkin Disease
69
Lymphoma, Mantle-Cell
65
Carcinoma, Renal Cell
62
Brain Neoplasms
56
Small Cell Lung Carcinoma
55
Squamous Cell Carcinoma of Head and Neck
54
Triple Negative Breast Neoplasms
52
Sarcoma
52
Interventions
derazantinib
2
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Has results
×
Acrocephalosyndactylia
×
Clear all
NCT04604132
2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2
Terminated
47 enrolled
22 charts
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts